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S332 Poster Session IIspleen and CD4+ Th17 cytokine (IL-17) elevation in the thymic
compartment of recipients that received S-59 treated T cells
(mean-28.44pg/ml versus 1.45pg/ml, p 5 0.0059). In-vivo track-
ing of S-59 treated T cells demonstrated the disappearance of
these cells in the peripheral blood, spleen, bone marrow and thy-
mus within 48 hours of transplantation. Nonetheless, we noted
that recipients of S-59 treated T cells had significantly less acute
GVHD and better overall survival (p 5 0.0001). In-vitro co-cul-
tures of stem cells (HSC) with S-59 T cells demonstrated signif-
icant increase in multilineage CFU formation(p \ 0.0001). In
summary, our experiments indicate that there is an initial domi-
nance of inflammatory and CD4 Th1 cytokines immediately
post transplantation. Co-transplantation of S-59 treated T cells
shifts the effector CD4 T cell profile to resemble a Treg pheno-
type. Thus, S-59 treated T cells appear to exert an important
immunomodulatory effect to ameliorate GVHD and improve
survival after MHC-mismatched allogeneic transplantation. In
addition these T cells exert a direct proliferative effect on the
HSCs.
Table 1. Cytokine Profile
Peripheral blood Bone marrow ThymocyteTGF-b [S59] 8482.7 pg/ml 7062.1pg/ml 2926.9pg/ml
TGF-b [control] 1.1pg/ml 301.55 pg/ml 46.5 pg/ml
IL-10 [S59] 419.0 pg/ml 174.0 30.4pg/ml
IL-10 [control] <1pg/ml 82.1pg/ml 33.44pg/mlp value- * 0.0001, **0.0006497
SIROLIMUS INDUCES COMPLETE REMISSION OF ACUTE GRAFT-VERSUS-
HOST DISEASE WITHOUT SYSTEMIC GLUCOCORTICOIDS
Pidala, J., Tomblyn, M., Nishihori, T., Perkins, J., Field, T., Ayala, E.,
Alsina, M., Ochoa, L., Locke, F., Perez, L., Fernandez, H., Anasetti, C.
Moffitt Cancer Center, Tampa, FL
While glucocorticoids have been considered essential in pri-
mary therapy of acute graft-versus-host disease (aGVHD), com-
plete remission from aGVHD is achieved in the minority of
cases. Sirolimus is a potent immunosuppressive agent which
may provide a novel approach to primary aGVHD therapy. In
a retrospective analysis, we examined the efficacy of sirolimus
as sole primary therapy for aGVHD. A total of 32 allogeneic
peripheral blood stem cell recipients (78% unrelated donors,
16% with 1-2 antigen mismatch) with biopsy confirmed aGVHD
were treated with sirolimus at a median of 30 days (range 15 –
106) after allogeneic hematopoietic cell transplantation (HCT).
Median age was 60 years (range 28–73). Patients were at high
risk for relapse of primary malignancy, with 23/32 not in remis-
sion at time of HCT. Sirolimus was delivered orally to achieve
serum levels of 4-12ng/mL. Therapeutic serum levels of siroli-
mus were achieved in all cases, including those with GI involve-
ment. All patients had tacrolimus based aGVHD prophylaxis;
target tacrolimus level was reduced to 3-7ng/mL once sirolimus
was initiated. Complete remission (CR) was defined as complete
resolution of all aGVHD manifestations sustained for at least 4
weeks without the addition of glucocorticoids or other systemic
immune suppressive agents. At time of primary sirolimus therapy,
53% had skin involvement, 66% GI, and 16% hepatic. Overall
grade was 1 (12%), 2 (75%), and 3 (13%). Sixteen (50%) achieved
sustained CR of aGVHD following sirolimus treatment. CR did
not significantly differ according to organ involvement or overall
aGVHD severity. With median follow up time of 16 months
(range 6-26 months), one year OS was 56% (95% CI 38-74%).
Accounting for competing risk, the cumulative incidence of
relapse at one year was 37% (23-60%), and NRM was 20%
(10-42%). The cumulative incidence of any grade chronic
GVHD per NIH consensus criteria was 55% (39-79%). Throm-
botic microangiopathy occurred in three cases, which responded
to dose reduction or elimination of calcineurin inhibitor.
Sirolimus demonstrates activity that rivals that of high dose
glucocorticoids in the primary therapy of aGVHD.498
RAPAMYCIN DELAYS XENOGENEIC ACUTE GRAFT VERSUS HOST DISEASE
(AGVHD) IN NOD/SCID/IL2RgNULL (NSG) MICE: IMPACT OF REGULA-
TORY T CELLS
Bruck, F., Baron, F., Dubois, S., Briquet, A., Hanon-Absil, M., Belle, L.,
Menten, C., Beguin, Y., Humblet-Baron, S. University of Liege, Liege,
Liege, Belgium
Background: Rapamycin (RAPA), a mTOR inhibitor also termed
sirolimus, is a potent immunosuppressive drug which might induce
tolerance by inhibiting activated T cells but not regulatory (Treg)
T cells. The aims of the current study were to establish a humanized
model of aGVHD in NSG mice, and to assess the impact of RAPA
and Treg infusion/depletion on morbidity from xenogeneic
aGVHD.
Methods andResults:Wefirst assessed the impact of the dose of IV
infused human PBMC on GVHD mortality. After 2.5 Gy TBI irra-
diation NSG mice received 5105 (n 5 5), 1106 (n 5 5), 2106
(n 5 5) or 3106 (n 5 5) human PBMC. Mean survivals in each
group were 3667 days, 3066 days, 2465 days and 1661 days,
respectively. At time of death, mice presented clinical symptoms of
aGVHDsuch as weight loss higher than. 20%, and showedmassive
CD3+ humanT cells infiltration of their marrows, livers, spleens and
lungs. Based on these results, we decided to use 2106 PBMC for
further experiments. We then investigated whether injection of
RAPA or PBMC supplemented in Treg could mitigate aGVHD in
this model. After receiving 2.5 Gy TBI NSGmice were transplanted
with 2106 PBMC and i.p. PBS (control arm), with 2106 PBMC
and i.p. RAPA (rapa arm), with 2106 PBMC depleted in Treg
and i.p. RAPA (Treg-depleted arm), or with 2106 PBMC supple-
mented in Treg (1Treg:8PBMC) and i.p. PBS (Treg arm). Mice
were daily monitored for survival and weighed at least once a week
until sacrifice. Median survival was higher in the RAPA arm than
in the control arm (96 vs. 24 days, P \ 0.01), while mice given
Treg-depleted PBMC plus RAPA had a median survival of 48 days
(P\ 0.01 in comparison with the rapa arm). In contrast, mice in
the Treg arm had a median survival of 71 days (P\0.01 in compar-
ison with the control arm).
Conclusions: In summary, our data indicate that i.v. injection of
2106 PBMC into irradiatedNSGmice induced a severe xenogeneic
aGVHD. RAPA administration increased survival but this effect was
greatly affected byTreg depletion suggesting that RAPA administra-
tion prevented death fromGVHDat least in part by promotingTreg.499
STAT1 DEFICIENCY FAILS TO PROTECT AGAINST MURINE CHRONIC
GVHD
Foley, J.E., Amarnath, S., Felizardo, T.C., He, A., Fowler, D.H.
National Cancer Institute, Bethesda, MD
Donor Th1 cells, which play a key role in promoting acute
GVHD, may also contribute to chronic GVHD. To further charac-
terize the role of Th1 cells in cGVHD, we used a model developed
by the Drobyski Lab whereby acute GVHD is initiated (B6 0
BALB/c BMT; 21-day transplant interval), with subsequent adoptive
transfer of post-BMT B6 T cells into syngeneic, immune-deficient
hosts (B6129s7-Rag1; 45-day observation interval) for induction of
auto-reactive, cGVHD. Because STAT1 is the signaling pathway
for the Th1-polarizing cytokines IFN-a and IL-12, we used
STAT1-deficient (KO) donor T cells to assess whether Th1 cell
deficiency might yield reduced cGVHD; other transplant cohorts
received T cells that were either wild-type (WT), STAT3-KO
(loss of Th17 function), or STAT6-KO (loss of Th2 function). Clin-
ical signs of acute GVHD (weight loss, hunched posture) was severe
in WT, mild in STAT3-KO, and STAT6-KO T cells; in contrast,
STAT1-KO T cell recipients showed no signs of acute GVHD.
Chronic GVHD, which was manifested by weight loss and extensive
skin disease (erythematous, scaling rash with alopecia; . 50% body
surface area), occurred in 100% of recipients of WT and STAT1-
KOT cells (5/5 and 10/10 cases, respectively); by comparison, exten-
sive skin disease was not observed in recipients of STAT3-KO or
STAT6-KO T cells (0/9 and 0/5 cases, respectively). As such,
STAT1-deficiency appeared to reduce acute GVHDbut not chronic
GVHD. Further experiments were performed at the end of the
cGVHD observation interval to confirm that recipients of
Poster Session II S333STAT1-deficient T cells were indeed deficient in Th1 cells
post-BMT. Relative to recipients of WT T cells, recipients of
STAT1-KO T cells had reduced capacity to secrete IFN-g
(46616664 vs. 26566281; p \ 0.03) and TNF-a (31546269 vs.
1872684; p \ 0.001) and reduced absolute numbers of splenic
CD4+IFN-g+ T cells (1461.9 vs .076.02; p \ 0.05) and
CD8+IFN-g+ T cells (4.161.2 vs. 0.86.1; p\0.05). As such, recip-
ients of STAT1-deficient T cells were indeed deficient in Th1-po-
larization post-BMT during cGVHD. Remarkably, relative to WT
T cell recipients, recipients of STAT-1 deficient T cells had in-
creased absolute numbers of post-BMT splenic CD4+IL-176 T
cells (0.260.05 vs 13.266.5.; p\ 0.05). These data indicate that
long-term post-BMT deficiency of Th1-type cells does not protect
against chronic GVHD, perhaps in part due to expansion of alterna-
tive pathogenic T cells such as the Th17 subset.500
THE ROLE OF COMPLEMENT SYSTEM IN THE PATHOGENESIS OF GRAFT
VERSUS HOST DISEASE
Cherry, M.A.1, Parekh, H.1, Yu, Z.2, Lerner, M.2, Selby, G.1, Holter, J.1
1Oklahoma University Health Sciences Center, Oklahoma City, OK;
2Oklahoma University Health Sciences Center, Oklahoma City, OK
Introduction: Graft-versus-host disease (GVHD) remains a major
cause of morbidity and mortality in bone marrow transplant
(BMT) recipients. GVHD is classically described as T-cell lympho-
cytic infiltration followed by destruction of tissue caused by differ-
ences in HLA. However, treatments aimed at other components of
the immune system have been successful, questioning this paradigm.
The role of the complement system in GVHD is limited. In solid tu-
mor transplantation, activation of the complement system and link to
preformed anti-HLA antibodies in recipients has been associated
with rejection.We describe the evaluation of complement activation
in 53 patients with clinical GVHD in whom40 specimens of skin and
7/13 specimens of colon showed evidence ofGVHDby conventional
histochemical staining method. In addition, we analyzed 11 control
patients with normal colon biopsies. Analysis of complement fixation
was performed using C4d antibody staining method and was
analyzed using the Banff07 grading system where minimal staining
is denoted as positive in\10% of vessels and diffuse staining is pos-
itive in . 50% of vessels. Histology of GVHD was correlated with
C4d deposition. Statistical analysis using Fisher’s exact test was
performed between groups and with controls.
Results: Thirty-four of forty skin biopsies were evaluable for C4d
deposition (6 specimens showing extensive background deposition
were excluded). Twenty-one of thirty-four specimens showed C4d
staining (11 minimal, 9 focal, and 1 diffuse). Twelve of the thirteen
colon biopsies showed C4d staining (2 minimal, 4 focal, and 6 dif-
fuse). Of the 11 control colon biopsies, 10 were negative for C4d
and 1 showed minimal staining. In the cohort that showed clinical
GVHD not pathologically confirmed, 6/6 showed C4d staining.
The difference in C4d staining between the GVHD of the colon
and colon control specimens was statistically significant using
a Fisher’s exact test (p-value 5 0.00000177). In addition, there was
statistical difference between Cd4 staining in clinical GVHD vs.
controls with a p value of 0.0000127.
Conclusion: Our results demonstrate that most patients with clini-
cal GVHD showed vascular staining for C4d. Clinical GVHD and
C4d deposition were closely correlated and statistically different
from controls. This may indicate that C4d positivity is a more
sensitive marker in detecting GVHD of the colon than classic
GVHD histological evaluation.501
SUSTAINED HIGH-DOSE CORTICOSTEROID USE DOES NOT INDEPEN-
DENTLY DIMINISH SURVIVAL AFTER MYELOABLATIVE ALLOGENEIC
HEMATOPOIETIC STEM CELL TRANSPLANTATION
Bejanyan, N.1, Lazaryan, A.1, Rybicki, L.2, Tench, S.3, Andresen, S.1,
Sobecks, R.3, Dean, R.3, Pohlman, B.3, Kalaycio, M.3, Bolwell, B.3,
Copelan, E.3 1Taussig Cancer Institute, Cleveland Clinic, Cleveland,
OH; 2Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH;
3Taussig Cancer Institute, Cleveland Clinic, Cleveland, OHIntroduction: Corticosteroids remain the most efficacious treat-
ment for acute GVHD (aGVHD) following allogeneic hematopoi-
etic stem cell transplantation (AlloHSCT). Some patients with
aGVHD receive high-dose (HD) corticosteroids for $ 2 months
for a variety of reasons. Morbidities related to long term corticoste-
roid use are well recognized, however, the impact of dosing and
treatment duration on survival has not been fully evaluated in the
post-AlloHSCT setting.
Methods: From 1998 to 2009, 272 patients with AlloHSCT were
treated with corticosteroids between post-transplant days 30 and
100 at a single academic institution. Patients in HD group received
$ 30 mg prednisone daily for$ 2 months, whereas those in the low-
dose (LD) corticosteroid group received\ 30 mg at some point in
this interval or $ 30 mg for\ 2 months. Relapse-free (RFS) and
overall survival (OS) were compared between corticosteroid groups.
Cox proportional hazards analysis identified prognostic factors.
Results:HD (n5 98) and LD (n5 174) groups were similar in dis-
tribution of demographic characteristics, comorbidity index, diagno-
sis, number of previous chemotherapies and conditioning regimen
(all p $ 0.3). HD group had more MUD AlloHSCT (p 5 0.05)
and higher-grade aGVHD (p\ 0.001). Malignancy relapse in HD
and LD groups was 24% and 36%, whereas overall mortality was
59% and 55% respectively. Non-relapse mortality tended to be
higher (HR 5 1.5; 95% CI, 1.0-2.3) in HD group. No significant
association was detected between the HD corticosteroid use and
infection-related mortality (p 5 0.1), relapse mortality (p 5 0.2),
RFS (p5 0.8), or OS (p5 0.4). Multivariable analysis of non-relapse
mortality demonstrated no independent prognostic significance of
HD corticosteroid use (HR 5 1.3; 95% CI, 0.8-2) after adjustment
for comorbidity index (HR 5 2 for high vs. low HCT-CI; 95% CI,
0.8-2), source of hematopoietic stem cells (HR 5 2.3 for peripheral
vs. bone marrow; 95%CI, 1.3-4.1) and grade of aGVHD (HR5 1.3
per 1 grade increase; 95% CI, 1.1-1.6).
Conclusions: Using HD corticosteroids for $ 2 months did not
appear to have an independent impact on patient survival following
AlloHSCT and therefore it may be safe to use as necessary for
aGVHD control. The association of HD steroids with non relapse
mortality appears to be related to worse aGVHD.502
THYMIC IRRADIATION IS REQUIRED FOR TRANSPLANTATION TOLER-
ANCE AFTER TLI/ATS NON-MYELOABLATIVE CONDITIONING
Ong, T.1, Van Der Merwe, M.1, Vogel, P.2, Pillai, A.1 1St. Jude Child-
ren’s Research Hospital, Memphis, TN; 2St. Jude Children’s Research
Hospital, Memphis, TN
Total Lymphoid Irradiation and Anti-Thymocyte Serum (TLI/
ATS) conditioning induces potent donor-host tolerance and
GVHD protection via induction of donor CD4+CD25+Foxp3+
Treg after bone marrow transplantation (BMT) (Pillai et al, Blood
2009). Whereas total body irradiation (TBI) at doses as low as 400
cGy associate with lethal acute GVHD after MHC-mismatched
BMT, TLI exposes GVHD target organs to a cumulative radiation
dose of 2400 to 4080 cGy, without GVHD. We investigated the
role of radiation exposure to specific anatomic areas in tolerance in-
duction after TLI/ATS + BMT. Wild-type (WT) BALB/c (H-2d)
hosts received infusion of 50 x 106 bone marrow + 60 x 106 spleno-
cytes from WT C57BL/6 (H-2b) donors (BMT) following 5 doses
of rabbit ATS + 10 doses (240 cGy each2400 cGy total) of fraction-
atedTBI, TLI, or TLIwith lead shielding of specific regions, includ-
ing TLI with focal thymic shielding (TLI-FTS). Day 6 H-
2Kb+CD8+ and H-2Kb+CD4+CD25neg effector cell and H-
2Kb+CD4+Foxp3+ Treg accumulation was quantified in target or-
gans, and GVHD scoring performed on histopathologic sections.
Positive controls included WT BALB/c hosts receiving ATS + sin-
gle-dose 800cGy TBI (PC-1) or ATS + 400 cGy TBI (PC-2) and
50 x 106 bone marrow + 60 x 106 splenocytes from C57BL/6 donors.
Negative controls received 800cGy TBI and 50 x 106 bone marrow
fromWTC57BL/6 (NC-1) or ATS alone + BMT (NC-2). All frac-
tionated TBI hosts died during conditioning with histopathologic
systemic radiation toxicity. In TLI/ATS hosts at day 6 after BMT,
accumulation of H-2Kb+TCR+CD8+ cells was strongly suppressed
in colon, MLN, and spleen (p\0.01), with increased accumulation
of donor Treg (p\0.01) compared to PC-1 controls. Mean colonic
